Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 853076, 11 pages
http://dx.doi.org/10.1155/2014/853076
Research Article

Comparison of Quasispecies Diversity of HCV between Chronic Hepatitis C and Hepatocellular Carcinoma by Ultradeep Pyrosequencing

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea
2Department of Laboratory Medicine, Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju 660-701, Republic of Korea
3Department of Laboratory Medicine, Sure Quest Laboratory, Yongin 446-916, Republic of Korea
4Department of Laboratory Medicine, College of Medicine, Korea University, Seoul 136-705, Republic of Korea
5Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea

Received 21 February 2014; Accepted 1 May 2014; Published 5 June 2014

Academic Editor: Mina Hur

Copyright © 2014 Chang-Wook Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Joyce and D. L. J. Tyrrell, “The cell biology of hepatitis C virus,” Microbes and Infection, vol. 12, no. 4, pp. 263–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. L. Fishman and A. D. Branch, “The quasispecies nature and biological implications of the hepatitis C virus,” Infection, Genetics and Evolution, vol. 9, no. 6, pp. 1158–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Argentini, D. Genovese, S. Dettori, and M. Rapicetta, “HCV genetic variability: from quasispecies evolution to genotype classification,” Future Microbiology, vol. 4, no. 3, pp. 359–373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Farci, A. Shimoda, A. Coiana et al., “The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies,” Science, vol. 288, no. 5464, pp. 339–344, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Amarapurkar, “Natural history of hepatitis C virus infection,” Journal of Gastroenterology and Hepatology, vol. 15, supplement, pp. E105–E110, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Alberti, L. Chemello, and L. Benvegnù, “Natural history of hepatitis C,” Journal of Hepatology, vol. 31, supplement 1, pp. 17–24, 1999. View at Google Scholar · View at Scopus
  7. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, no. 5, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. D. G. Bowen and C. M. Walker, “Adaptive immune responses in acute and chronic hepatitis C virus infection,” Nature, vol. 436, no. 7053, pp. 946–952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Qin, N. J. Shire, E. D. Keenan et al., “HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV,” Blood, vol. 105, no. 2, pp. 533–541, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Honda, S. Kaneko, A. Sakai, M. Unoura, S. Murakami, and K. Kobayashi, “Degree of diversity of hepatitis C virus quasispecies and progression of liver disease,” Hepatology, vol. 20, no. 5, pp. 1144–1151, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Naito, N. Hayashi, T. Moribe et al., “Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease,” Hepatology, vol. 22, no. 2, pp. 407–412, 1995. View at Google Scholar · View at Scopus
  12. J. M. Pawlotsky, M. Pellerin, M. Bouvier et al., “Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C,” Journal of Medical Virology, vol. 54, pp. 256–264, 1998. View at Google Scholar
  13. F.-X. López-Labrador, S. Ampurdaǹs, M. Giménez-Barcons et al., “Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon,” Hepatology, vol. 29, no. 3, pp. 897–903, 1999. View at Google Scholar · View at Scopus
  14. K. Koizumi, N. Enomoto, M. Kurosaki et al., “Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment,” Hepatology, vol. 22, no. 1, pp. 30–35, 1995. View at Google Scholar · View at Scopus
  15. D. G. Sullivan, D. Bruden, H. Deubner et al., “Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease,” Journal of Infectious Diseases, vol. 196, no. 2, pp. 239–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Shendure and H. Ji, “Next-generation DNA sequencing,” Nature Biotechnology, vol. 26, no. 10, pp. 1135–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. V. Voelkerding, S. A. Dames, and J. D. Durtschi, “Next-generation sequencing:from basic research to diagnostics,” Clinical Chemistry, vol. 55, no. 4, pp. 641–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. L. Metzker, “Sequencing technologies—the next generation,” Nature Reviews Genetics, vol. 11, no. 1, pp. 31–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Solmone, D. Vincenti, M. C. F. Prosperi, A. Bruselles, G. Ippolito, and M. R. Capobianchi, “Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen,” Journal of Virology, vol. 83, no. 4, pp. 1718–1726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Margeridon-Thermet, N. S. Shulman, A. Ahmed et al., “Ultra-deep pyrosequencing of hepatitis b virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients,” Journal of Infectious Diseases, vol. 199, no. 9, pp. 1275–1285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Varghese, R. Shahriar, S.-Y. Rhee et al., “Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors,” Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 3, pp. 309–315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Hedskog, M. Mild, J. Jernberg et al., “Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing,” PLoS ONE, vol. 5, no. 7, Article ID e11345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Yuki, N. Hayashi, T. Moribe et al., “Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies,” Hepatology, vol. 25, no. 2, pp. 439–444, 1997. View at Google Scholar · View at Scopus
  24. K. L. Barlow, J. Green, and J. P. Clewley, “Viral genome characterisation by the heteroduplex mobility and heteroduplex tracking assays,” Reviews in Medical Virology, vol. 10, pp. 321–335, 2000. View at Google Scholar
  25. J. Hayashi, Y. Kishihara, K. Yamaji et al., “Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection,” Hepatology, vol. 25, no. 3, pp. 697–701, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Curran, C. L. Jameson, J. K. Craggs et al., “Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity,” Journal of General Virology, vol. 83, no. 1, pp. 11–23, 2002. View at Google Scholar · View at Scopus
  27. K. Yusim, R. Richardson, N. Tao et al., “Los Alamos hepatitis C immunology database,” Applied Bioinformatics, vol. 4, no. 4, pp. 217–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Soresi, C. Magliarisi, P. Campagna et al., “Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma,” Anticancer Research, vol. 23, no. 2, pp. 1747–1753, 2003. View at Google Scholar · View at Scopus
  30. F. Trevisani, P. E. D'Intino, A. M. Morselli-Labate et al., “Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status,” Journal of Hepatology, vol. 34, no. 4, pp. 570–575, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Gambarin-Gelwan, D. C. Wolf, R. Shapiro, M. E. Schwartz, and A. D. Min, “Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation,” American Journal of Gastroenterology, vol. 95, no. 6, pp. 1535–1538, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. I. C. Weitz and H. A. Liebman, “Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review,” Hepatology, vol. 18, no. 4, pp. 990–997, 1993. View at Google Scholar · View at Scopus
  33. T. Nakagawa, T. Seki, T. Shiro et al., “Clinicopathologic significance of protein induced vitamin K absence or antagonist II and α-fetoprotein in hepatocellular carcinoma,” International Journal of Oncology, vol. 14, no. 2, pp. 281–286, 1999. View at Google Scholar · View at Scopus